GOODWILL AND OTHER INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

Changes in the carrying amount of goodwill for the six-month period ended June 30, 2021 were as follows:


Dollars in thousands	Codman Specialty Surgical		Tissue Technologies		Total


Goodwill at December 31, 2020	$	671,975	$	260,392	$	932,367



ACell Acquisition	—		94,298		94,298



Foreign currency translation	(7,218)		(3,809)		(11,027)
Goodwill at June 30, 2021	$	664,757	$	350,881	$	1,015,638

The components of the Company’s identifiable intangible assets were as follows:


	June 30, 2021
Dollars in thousands	Weighted Average Life	Cost		Accumulated Amortization		Net
Completed technology	18 years	$	1,125,279	$	(274,287)	$	850,992
Customer relationships	12 years	$	212,572	$	(137,897)	$	74,675
Trademarks/brand names	28 years	$	99,319	$	(29,866)	$	69,453
Codman tradename	Indefinite	$	166,651	$	—	$	166,651
Supplier relationships	30 years	$	30,211	$	(15,691)	$	14,520
All other	11 years	$	6,473	$	(3,880)	$	2,593


		$	1,640,505	$	(461,621)	$	1,178,884


	December 31, 2020
Dollars in thousands	Weighted Average Life	Cost		Accumulated Amortization		Net
Completed technology	19 years	$	896,478	$	(248,088)	$	648,390
Customer relationships	12 years	213,270		(132,838)		80,432
Trademarks/brand names	28 years	104,209		(31,767)		72,442
Codman tradename	Indefinite	170,226		—		170,226
Supplier relationships	27 years	30,211		(15,203)		15,008
All other (1)	4 years	6,693		(3,755)		2,938
		$	1,421,087	$	(431,651)	$	989,436

(1) Prior period amounts were reclassified as it relates to All other within this table to conform to the current period presentation.

The increase in the Company's identifiable intangible assets at June 30, 2021 as compared to the year ended December 31, 2020, was primarily driven from intangible assets acquired in conjunction with the ACell Inc. acquisition. See Note 2, Acquisitions and Divestitures, for details.

Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of product revenues) is expected to be approximately $40.6 million for the remainder of 2021, $79.1 million in 2022, $78.4 million in 2023, $77.7 million in 2024, $77.7 million in 2025, $77.5 million in 2026 and $585.7 million thereafter.